Keywords: Johnson & Johnson, Janssen, Prezista, HIV, CRL, USA, FDA, Teva, Adderall, Counterfeit

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall

Article | 30 May 2012

Print This

US health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen Therapeutics division has received a complete response letter ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in